{"id":"tazarotene-0-1-gel","safety":{"commonSideEffects":[{"rate":"20-40","effect":"Skin irritation (erythema, peeling, dryness)"},{"rate":null,"effect":"Photosensitivity"},{"rate":"10-20","effect":"Burning or stinging sensation"},{"rate":"5-15","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL1657","moleculeType":"Small molecule","molecularWeight":"351.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a third-generation retinoid, tazarotene selectively activates RXR and RAR nuclear receptors, which modulate transcription of genes involved in cell proliferation, differentiation, and inflammation. This leads to normalization of keratinization, reduced sebum production, and anti-inflammatory effects in the skin. The mechanism makes it effective for treating acne and psoriasis by promoting epidermal cell turnover and reducing comedone formation.","oneSentence":"Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:14.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acne vulgaris"},{"name":"Plaque psoriasis"},{"name":"Photoaging and facial wrinkles"}]},"trialDetails":[{"nctId":"NCT04071756","phase":"PHASE2","title":"Topical Tazarotene Vs Placebo In Hand-Foot-Skin Reactions","status":"TERMINATED","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-12-30","conditions":"Solid Tumor, Hand-Foot Skin Reaction (HFSR)","enrollment":8},{"nctId":"NCT05555797","phase":"PHASE4","title":"Excimer Laser With Topical Agents in Psoriasis Vulgaris","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-10-30","conditions":"Psoriasis","enrollment":30},{"nctId":"NCT05573425","phase":"PHASE2, PHASE3","title":"Comparing the Efficacy of Topical Tazarotene Gel 0.1% v/s Microneedling in Atrophic Post Acne Scars","status":"COMPLETED","sponsor":"Jinnah Postgraduate Medical Centre","startDate":"2020-08-22","conditions":"Acne Scar","enrollment":202},{"nctId":"NCT00469755","phase":"PHASE4","title":"Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2006-02","conditions":"Acne Vulgaris","enrollment":302},{"nctId":"NCT05314127","phase":"PHASE2","title":"Efficacy of Tazarotene in Treatment of Verruca Plana","status":"UNKNOWN","sponsor":"Zagazig University","startDate":"2022-04-15","conditions":"Warts Flat","enrollment":80},{"nctId":"NCT01616654","phase":"PHASE2","title":"Dose Range Study of CD5789 in Acne Vulgaris","status":"COMPLETED","sponsor":"Galderma R&D","startDate":"2012-06-20","conditions":"Acne Vulgaris","enrollment":304},{"nctId":"NCT01094717","phase":"NA","title":"Acitretin or Tazarotene Gel and Excimer Laser for Treatment of Psoriasis","status":"TERMINATED","sponsor":"University of Utah","startDate":"2010-01","conditions":"Psoriasis","enrollment":13},{"nctId":"NCT03170596","phase":"NA","title":"Comparison Between Microneedling Daycare Procedure and Tazarotene 0.1% Gel Local Application in Acne Scarring","status":"COMPLETED","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2017-06-02","conditions":"Atrophic Post Acne Scarring","enrollment":36},{"nctId":"NCT01019603","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Tazarotene Foam, 0.1%, and Tazorac Gel, 0.1%, in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10-12","conditions":"Acne Vulgaris","enrollment":30},{"nctId":"NCT00713609","phase":"PHASE2","title":"Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2008-06","conditions":"Acne Vulgaris","enrollment":591},{"nctId":"NCT01016977","phase":"PHASE4","title":"A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-10","conditions":"Acne Vulgaris","enrollment":40},{"nctId":"NCT02721173","phase":"PHASE4","title":"Tazarotene Plus Clindamycin vs. Adapalene Plus Clindamycin in the Treatment of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2016-04","conditions":"Acne Vulgaris","enrollment":60},{"nctId":"NCT01053000","phase":"NA","title":"Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses","status":"COMPLETED","sponsor":"Stewart, Roger H., M.D., P.A.","startDate":"2010-01","conditions":"ACTINIC KERATOSES","enrollment":10},{"nctId":"NCT02218034","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AGN-190168 in Subjects With Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2014-08","conditions":"Acne Vulgaris","enrollment":78},{"nctId":"NCT00829049","phase":"PHASE4","title":"Safety and Efficacy of Tazarotene Cream 0.1% Compared With Adapalene Gel 0.3% in the Treatment of Moderate to Severe Facial Acne Vulgaris","status":"TERMINATED","sponsor":"Allergan","startDate":"2007-10","conditions":"Acne Vulgaris","enrollment":165},{"nctId":"NCT00834210","phase":"PHASE4","title":"Dapsone Gel 5% and Tazarotene Cream 0.1% Versus Tazarotene Cream 0.1% Monotherapy for Facial Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-12","conditions":"Acne Vulgaris","enrollment":171},{"nctId":"NCT00145106","phase":"PHASE4","title":"Comparison of Tazarotene and Minocycline Therapies for Maintenance of Facial Acne Vulgaris","status":"COMPLETED","sponsor":"KGL, Inc.","startDate":"2002-03","conditions":"Acne Vulgaris","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":53,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazret gel 0.1%","TAZORAC® Gel 0.1%","TAZORAC® Cream 0.1%","Tazarotene","tazarac"],"phase":"marketed","status":"active","brandName":"Tazarotene 0.1% gel","genericName":"Tazarotene 0.1% gel","companyName":"Galderma R&D","companyId":"galderma-r-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tazarotene is a retinoid that binds to retinoid X receptors (RXR) and retinoid acid receptors (RAR) to regulate gene expression and promote skin cell differentiation and turnover. Used for Acne vulgaris, Plaque psoriasis, Photoaging and facial wrinkles.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}